155 related articles for article (PubMed ID: 37066265)
1. Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time.
Shaaban A; Petersen A; Beckwith H; Florea N; Potter DA; Yee D; Vogel RI; Duprez D; Blaes AH
Res Sq; 2023 Apr; ():. PubMed ID: 37066265
[TBL] [Abstract][Full Text] [Related]
2. Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time.
Shaaban A; Petersen A; Beckwith H; Florea N; Potter DA; Yee D; Vogel RI; Duprez D; Blaes AH
Cardiooncology; 2024 May; 10(1):27. PubMed ID: 38693561
[TBL] [Abstract][Full Text] [Related]
3. Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study.
Blaes A; Beckwith H; Florea N; Hebbel R; Solovey A; Potter D; Yee D; Vogel R; Luepker R; Duprez D
Breast Cancer Res Treat; 2017 Nov; 166(2):541-547. PubMed ID: 28801846
[TBL] [Abstract][Full Text] [Related]
4. The role of aromatase inhibitors in early breast cancer.
Chung CT; Carlson RW
Curr Treat Options Oncol; 2003 Apr; 4(2):133-40. PubMed ID: 12594939
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
6. Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer.
Maor R; Sara JDS; Wanous AA; Maor E; Pruthi S; Lerman A; Sandhu NP
Coron Artery Dis; 2018 Dec; 29(8):687-693. PubMed ID: 30379695
[TBL] [Abstract][Full Text] [Related]
7. Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.
Younus M; Kissner M; Reich L; Wallis N
Drug Saf; 2011 Dec; 34(12):1125-49. PubMed ID: 22077502
[TBL] [Abstract][Full Text] [Related]
8. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Nabholtz JM; Gligorov J
Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
12. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Taichman LS; Van Poznak CH; Inglehart MR
Support Care Cancer; 2016 Nov; 24(11):4815-24. PubMed ID: 27455851
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Psychological measures of stress and biomarkers of inflammation, aging, and endothelial dysfunction in breast cancer survivors on aromatase inhibitors.
Blaes AH; Nair C; Everson-Rose S; Jewett P; Wolf J; Zordoky B
Sci Rep; 2023 Jan; 13(1):1677. PubMed ID: 36717689
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
16. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
17. Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial.
Prasad C; Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
Bone; 2016 Sep; 90():123-6. PubMed ID: 27018037
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
Qian X; Li Z; Ruan G; Tu C; Ding W
Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson L; Lawrence D; Dawson C; Bliss J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
